logo

Global Blood Therapeutics (GBT)



Trade GBT now with
  Date
  Headline
8/23/2018 8:07:37 AM Global Blood Therapeutics Enters Exclusive Worldwide Licensing Agreement With F. Hoffmann-La Roche
8/6/2018 7:27:29 AM Wedbush Is Raising Global Blood Therapeutics (GBT) FY19 Estimate To -3.64 From -3.65
8/6/2018 7:27:10 AM Wedbush Is Increasing Global Blood Therapeutics (GBT) Q4 19 Estimate To -0.89 From -0.90
8/6/2018 7:26:49 AM Wedbush Is Raising Global Blood Therapeutics (GBT) FY18 Estimate To -3.39 From -3.44
8/6/2018 7:26:21 AM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $73 Up From $70 Price Target
6/27/2018 7:42:16 AM Global Blood Therapeutics, Trading Expected To Resume At 8:00 AM ET
6/27/2018 7:33:31 AM BT Announces Top-line Data From Part A Of The Phase 3 HOPE Study Of Voxelotor Meets Primary Endpoint
6/27/2018 7:28:24 AM Global Blood Therapeutics, Trading Halt Pending News
6/18/2018 2:06:31 PM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $70 Price Target
6/15/2018 2:35:07 AM GBT Announces New Phase 2a Voxelotor Data In Adolescents With Sickle Cell Disease
6/7/2018 12:32:55 PM BMTC Group Q1 EPS $0.13 Vs. Breakeven Year Go
5/25/2018 2:34:24 PM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $70 Price Target
3/14/2018 6:27:29 AM Wedbush Is Lowering Global Blood Therapeutics (GBT) FY18 Estimate To -3.71 From -2.80
3/14/2018 6:27:12 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q4 18 Estimate To -0.97 From -0.73
3/14/2018 6:27:01 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q3 18 Estimate To -0.94 From -0.71
3/14/2018 6:26:45 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q2 18 Estimate To -0.92 From -0.69